

IBM Micromedex

Shou Ray Information Service

2022

大綱

Micromedex 內容簡介

Micromedex 使用介面


在 Micromedex 中查找藥物資訊

Ask Watson – 有問題，問華生！

Micromedex 內容簡介

Micromedex 收錄內容範圍

Micromedex® Solutions Healthcare Series



內容特性

◆ Authority 權威性

- ◆ DrugDex, Poisindex, DiseaseDex Emergency Medicine was adapted by U.S, Department of State as official medical encyclopedia

◆ Quality 高品質

- ◆ Strict editorial process

◆ Reliability 專業可靠

- ◆ Provide service for schools, hospitals , and pharmaceutical companies over 30 years

◆ Consistency 一致性

- ◆ Consistency formats and standards

◆ Full-text databases 全文閱讀

- ◆ Fully referenced, Peer reviewed, Written by clinicians

資料來源

Drug Information	Disease Information
DRUGDEX[®] System DRUG-REAX[®] System	DISEASEDEX[™] General Medicine DISEASEDEX[™] Emergency Med.
MARTINDALE Index Nominum Physicians' Desk Reference[®](PDR[®]) P & T QUIK[®] Reports	Lab adviser[™]
IV INDEX[®] System MSDS from USP	Patient Education
IDENTIDEX[®] System Red Book[®] Online KINETIDEX[®] System	AltCareDex[®] Alternative Medicine Education CareNotes[™] System
Alternative Medicine	Toxicology Information
AltMedDex[®] System AltMedDex[®] Protocols	POISINDEX[®] System TOMES[®] System REPRORISK[®] System
	Free Resources
	Calculators Micromedex Apps

Micromedex 使用介面

主頁

藥物
相互作用

IV 相容性

藥物
鑒定

藥物
比較

CareNotes

NeoFax® /
Pediatrics

其他工具 ▾

搜尋藥物、疾病、毒理學及其他資訊

全部

藥物

疾病

毒理學

Keyword search

1 檢索區

Ask Watson

Search Micromedex drug information

Type a quick question...

Learn more ?



最新消息

4

- Caplyta(R) for Schizophrenia
- Lynparza(R) Now for Pancreatic Cancer
- Ubrelvy(TM) to Treat Migraine
- Dayvigo(TM): Insomnia Treatment
- Enhertu(R) for HER2+ Breast Cancer

Read Top News



支援和訓練

5

- Citing Micromedex
- Clinical Consulting & Services
- Integrated Content Options for MU & More
- Product User Tips & Quick Answers
- Training Center
- User Guide

Support Request



資源

6

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS



Download Mobile Apps

資料庫登入方式

- **IP認證機制**
 - 在IP範圍內，從單位圖書館網頁連結
 - 利用校 / 院外連線設定Proxy或VPN
 - 有同時上線人數限制 **養成好習慣，用完要登出**
- **行動載具APP 訂戶專屬**
 - 每次登入會自動更新資料
 - 可離線使用，不受網路死角影響

資料庫使用方式

機構IP範圍內

需有網路連線

上線人數限制

完整全文內容

行動載具APP

無需網路連線


無人數限制

僅有簡要解答


APP下載



IBM Micromedex Drug
Ref
IBM



IBM Micromedex Drug
Interact
IBM



IBM Micromedex IV
Compat
IBM



可離線使用，不受制於使用人數

APP使用方式



IBM mobileMicromedex®
Put the power of Micromedex on your mobile device

IBM
IBM Micromedex
IV Comp.

This app is free only for clinicians ("subscribers") who work at a hospital or facility with an online subscription to IBM Micromedex®. Subscribers can obtain their password by signing into Micromedex and following the "Download Center" link at the top of the page - or by simply contacting our Support Center.

The password only needs to be entered once per year.

Need Help? Not sure if you work at a hospital or facility that subscribes to Micromedex? Can't find the link to the password? Visit Our Support Center.

www.micromedex.com/mobile

Once you've obtained your password, please enter it below:

APP Password

Please provide a password to continue.

Accessing IBM Micromedex with Watson for Mobile Browsers

Accessing IBM Micromedex with Watson

Micromedex Apps on Mobile Devices

IBM Micromedex® Drug Int.



- The **IBM Micromedex Drug Int.** app for Apple, and Android devices is available for FREE for Micromedex subscribers.
- You can access these apps via the App Store (Apple devices) or Google Play® (Android devices).
- You can activate the app by following the simple instructions below.

Simple instructions for installation:

- Step 1:** Visit the App Store from your device and search IBM Micromedex Drug Int.
- Step 2:** From the App, select download / install the application. You may be prompted to enter your Apple or Google ID.
- Step 3:** The app will download to your app library, or directly to your device.
- Step 4:** Open the app. Enter the password begin using **IBM Micromedex Drug Int.** *The password is case-sensitive. Please enter it exactly as it appears here.*

Interactions	
aspi	
Drug List	Selected Drugs
Aspirin	✓
Aspirin/Butalbital/Caffeine	+
Aspirin/Caffeine/Dihydrocodeine Bitartrate	+
Aspirin/Codeine Phosphate	+
Aspirin/Dipyridamole	+
Aspirin/Omeprazole	+
Aspirin/Oxycodone Hydrochloride	+
Aspirin/Pravastatin Sodium	+
Aspirtab (Aspirin)	+
Aggrenox (Aspirin/Dipyridamole)	+
Anacin Aspirin Free (Acetaminophen)	+
Ascomp w/Codeine (Butalbital/Aspirin/Caffeine/Codeine Phosphate)	+

Interactions

Drug List Selected Drugs


- Warfarin Sodium
- Aspirin

Clear All View Interactions

Interactions

✓ Major

Ⓢ Warfarin Sodium : Aspirin



Interactions

Warfarin Sodium : Aspirin

Severity: Major

Onset: Not Specified

Documentation: Fair

Interaction Effect:

Concurrent use of WARFARIN and ANTIPLATELET AGENTS may result in increased risk of bleeding.


Clinical Management:

Coadministration of warfarin and antiplatelet agents may increase the risk of bleeding. Monitor patients closely for signs or symptoms of bleeding (Prod Info Jantoven(R) oral tablets, 2014) and evaluate promptly. Lab monitoring may be appropriate.

Probable Mechanism:
additive effects

APP小提醒

- 只有**簡要解答 (Summary)**
 - 深入解答仍需回到Micromedex網頁查詢
- 密碼到期
 - 新密碼的取得須在**IP範圍內登入**Micromedex 資料庫，進入 **下載中心** 頁面或  即可找到。



我的訂閱

IBM Micromedex®

我的訂閱 | 簡道 | Training Center | 說明 | 下載中心 | 登出

主頁 | 藥物相互作用 | IV 相容性 | 藥物鑒定 | 藥物比較 | CareNotes | NeoFax® / Pediatrics | 其他工具 ▾
















搜尋藥物



已經訂購

尚未訂購

Watson
micromedex drug information


MICROMEDEX
用於 Shou Ray Information Service Co Ltd.

Your Subscribed Products	Non-subscribed Products
<p>MICROMEDEX</p> <ul style="list-style-type: none">  AAPCC Codes in POISINDEX®  Alternative Medicine  Detailed Drug Information for the Consumer  DISEASEDEX™ Emergency Medicine  DISEASEDEX™ General Medicine  DRUGDEX® System  Imprint Codes in Identidex®  Index Nominum  Interaction Checking  Italian Drug Database  IV Compatibility  Lab Advisor™  MARTINDALE  MSDS from USP 	<p>MICROMEDEX</p> <ul style="list-style-type: none">  PharmacyXpert

列印  關閉 






資源

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS



 Download Mobile Apps

Your Subscribed Products

MICROMEDEX

-  Alternative Medicine
-  DRUGDEX® System
-  Imprint Codes in Identidex®
-  Interaction Checking
-  IV Compatibility


















補充用藥：

-  Calculators
-  mobileMicromedex

外部應用：

Non-subscribed Products





MICROMEDEX

-  AAPCC Codes in POISINDEX®
-  Detailed Drug Information for the Consumer
-  DISEASEDEX™ Emergency Medicine
-  DISEASEDEX™ General Medicine
-  Index Nominum
-  Italian Drug Database
-  Lab Advisor™
-  MARTINDALE
-  MSDS from USP
-  P&T QUIK® Reports
-  PDR®
-  POISINDEX® Managements
-  POISINDEX® System
-  RED BOOK Online®
-  REPRORISK® System
-  TOMES® System
-  United Kingdom Drug Information

補充用藥：

N/A

外部應用：

-  CareNotes®
-  Formulary Advisor®
-  NeoFax®
-  Pediatrics

Training Center

最新消息

- Caplyta(R) for Schizophrenia
- Lynparza(R) Now for Pancreatic Cancer
- Ubrelvy(TM) to Treat Migraine
- Dayvigo(TM): Insomnia Treatment
- Enhertu(R) for HER2+ Breast Cancer

Read Top News



支援和訓練

- Citing Micromedex
- Clinical Consulting & Services
- Integrated Content Options for MU & More
- Product User Tips & Quick Answers
- Training Center
- User Guide

Support Request



資源

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS



Download Mobile Apps

IBM Micromedex®

Click the **Header** (blue bar) to view the list of courses | Then click the **Title** link for a description of the course

^ Quick Tips

^ Overviews

^ Tools & Apps

^ Micromedex in Your Workflow

^ Toxicology

^ International

^ Guides

- IBM ActionOI®
 - IBM ActionOI Practice Insights®
- IBM CareDiscovery®
- IBM CareDiscovery® Electronic Quality Measures
- IBM CareDiscovery® Quality Measures
- IBM Market Expert®
- IBM Market Expert® State Data Scope
- IBM Micromedex® Clinical Knowledge
 - IBM Micromedex®
 - IBM Micromedex® (Integrated)
 - IBM Micromedex® NeoFax® and Pediatrics
 - IBM Micromedex® Pharmaceutical Knowledge
 - IBM Micromedex® RED BOOK®
 - IBM Micromedex® Formulary
- IBM Micromedex® Patient Connect
 - IBM Micromedex® CareNotes®
 - IBM Micromedex® CareNotes® (Integrated)

使用說明(Help)

IBM Micromedex®

我的訂閱 | 簡道 | Training Center | **說明** | 下載中心 | 登出

主頁 | 藥物相互作用 | IV 相容性 | 藥物鑑定 | 藥物比較 | CareNotes | NeoFax® / Pediatrics | 其他工具 ▾

搜尋藥物、疾病、毒理學及其他資訊

Ask Watson

Micromedex Solutions Help - Google Chrome

micromedexsolutions.com/micromedex2/4.320.0/WebHelp/MICROMEDEX_2.htm?navitem=headerHelp#Home_Page/Searching/Searching.htm#_Landing_Pages

CONTENTS INDEX SEARCH GLOSSARY

Overview
Micromedex Solutions Overview
Home Page
Overview
Latest News
Support and Training
Resources (Targeted Searches)
My Subscription
Toolbar
Watson Assistant
Searching
Searching
Landing Pages
Direct Access Searching
Brand Name Drugs
Intelligent Searching
Filtered Searching
Targeted Searches
Salt/Base Forms, Combo Kits
Intermediate Search Results
International Drug Searching
Targeted Searches
Results for Targeted Searches
IBM Micromedex Pharmaceutical Kn
Content
Tools
Micromedex on Your Mobile Device
Other Applications

Home > Home Page > Overview

IBM Micromedex® Home Page

Searches Made Simple

With the prominently displayed **Keyword** search box that is available on every page in IBM Micromedex® you have direct access to the information you need. It also provides intelligent searching with in-line spelling suggestions.

By default you can quickly perform one search to get all the relevant results for the content to which you subscribe, or you can specify a filter option to search specifically within the drug, disease, or toxicology content, which will provide you with more targeted results.

All is the default selection

Search Drug, Disease, Toxicology, and more

Click Drug, Disease, or Toxicology to activate the filter

All Drug Disease Toxicology

Keyword search

Read Top News

Support Request

Download Mobile Apps

最新消息

- Caplyta(R) for Schizophrenia
- Lynparza(R) Now for Pancreatic Cancer
- Ubrelvy(TM) to Treat Migraine
- Dayvigo(TM): Insomnia Treatment
- Enhertu(R) for HER2+ Breast Cancer

支援和訓練

- Citing Micromedex
- Clinical Consulting & Services
- Integrated Content Options for MU & More

資源

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List



Latest News

關閉 X

Read Top News

▼ Caplyta(R) for Schizophrenia

On December 23, 2019, the US FDA approved Caplyta(R) (lumateperone) oral capsules indicated for the treatment of schizophrenia in adult patients. Caplyta demonstrated efficacy with a significantly improved Positive and Negative Syndrome Scale total score compared with placebo in 2 clinical trials. Caplyta carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis and is not approved for this indication.

The prescribing information can be found at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf.

The monograph for lumateperone can be found at: <http://www.micromedexsolutions.com/micromedex2/librarian/deeplinkaccess?source=deepLink&SearchTerm=lumateperone>.

Last modified: 01/03/2020 11:40:24

Full Article

▶ Lynparza(R) Now for Pancreatic Cancer

▶ Ubrelvy(TM) to Treat Migraine

▶ Dayvigo(TM): Insomnia Treatment

▶ Enhertu(R) for HER2+ Breast Cancer

最新消息

- Caplyta(R) for Schizophrenia
- Lynparza(R) Now for Pancreatic Cancer
- Ubrelvy(TM) to Treat Migraine
- Dayvigo(TM): Insomnia Treatment
- Enhertu(R) for HER2+ Breast Cancer

支援和訓練

- Citing Micromedex
- Clinical Consulting & Services
- Integrated Content Options for MU & More
- Product User Tips & Quick Answers
- Training Center
- User Guide

資源

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS

HOW TO REFERENCE THE Truven Health Analytics SYSTEMS

[↑ Top of page](#)

PLEASE NOTE: When referencing a Micromedex product or database, you *must* include: (electronic version), Truven Health Analytics information, URL address (<http://www.micromedexsolutions.com/>) and the date accessed.

Subscribers to the Licensed Solutions often ask how to reference the databases when publishing articles. The following formats should be used:

The entire Micromedex System:

[↑ Top of page](#)

Micromedex® (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> (cited: *month/day/year*).

An entire System or Database:

[↑ Top of page](#)

IBM Micromedex® Alternative Medicine:

IBM Micromedex® Alternative Medicine (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> (cited: *month/day/year*).

CareNotes®:

CareNotes® (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> (cited: *month/day/year*).

IBM Micromedex® Disease Emergency Medicine:

IBM Micromedex® Disease - Emergency Medicine (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> (cited: *month/day/year*).

IBM Micromedex® Disease General Medicine:

IBM Micromedex® Disease - General Medicine (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> (cited: *month/day/year*).

Read Top News

常用資源 RESOURCES

最新消息

- Caplyta(R) for Schizophrenia
- Lynparza(R) Now for Pancreatic Cancer
- Ubrelvy(TM) to Treat Migraine
- Dayvigo(TM): Insomnia Treatment
- Enhertu(R) for HER2+ Breast Cancer

Read Top News



支援和訓練

- Citing Micromedex
- Clinical Consulting & Services
- Integrated Content Options for MU & More
- Product User Tips & Quick Answers
- Training Center
- User Guide

Support Request



資源

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS



Download Mobile Apps

以藥物首字母序條列有黑框警告的藥物
 意即研究表明該藥物具有嚴重的甚至危及生命的不良反應風險，是美國食品藥品監督管理局（FDA）對上市藥物採取的最嚴厲警告形式

黑框警告

跳轉到： A B C D E F G H I J K L M N **O** P Q R S T U V W X Y Z 0-9

顯示 30 of 999 條結果，帶有黑框警告

Obeticholic Acid

Obiltoximab

Obinutuzumab

Ofatumumab

Ofloxacin

Olanzapine

Olanzapine Pamoate

Ofloxacin

Drug Classes: [Antibacterial](#) | [Antibiotic](#) | [All](#)

Routes: [Ophthalmic](#) | [Oral](#) | [Otic](#)

Regulatory Authority

FDA

簡要解答
深入解答
全部結果

Dosing/Administration

Adult Dosing

Pediatric Dosing

FDA Uses

Non-FDA Uses

Dose Adjustments

Administration

Comparative Efficacy

Place In Therapy

Medication Safety

Contraindications

Precautions

Adverse Effects

Black Box Warning

Medication Safety

Black Box Warning [列印](#)

請參閱 '深入解答' 瞭解詳細結果。

Oral (Tablet)

- Fluoroquinolones, including ofloxacin, are associated with disabling and potentially irreversible serious adverse reactions that have occurred together, including tendinitis and tendon rupture, peripheral neuropathy, and CNS effects. Discontinue ofloxacin and avoid use of fluoroquinolones in patients with these serious adverse reactions. Reserve use of ofloxacin for patients with no alternative treatment options for acute exacerbation of chronic bronchitis or uncomplicated cystitis. Fluoroquinolones, including ofloxacin, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid in patients with known history of myasthenia gravis [2].

相關結果

[替代藥物](#)

[毒理學](#)

[疾病](#)

[Drug Consults](#)

[Index Nominum](#)

[Martindale](#)

[PDR®](#)

[Product Lookup - Martindale](#)

[Product Lookup - RED Book](#)

[Product Lookup - Tox & Drug](#)

[消費者藥物資訊](#)

Ask Watson

Dosage

Class

▶ BENZODIAZEPINES (SELECTED)

▶ CORTICOSTEROIDS (SELECTED) PROPERTIES AND POTENCIES

▶ NSAID (NONSTEROIDAL ANTIINFLAMMATORY AGENTS (SELECTED))

Oral NSAIDs

Generic Name	Brand Name (US)	Indications	Effective Dosage Range
Diclofenac	Cataflam (diclofenac potassium immediate-release tablets)	Pain	50 mg 3 times daily
		Dysmenorrhea	50 mg 3 times daily
		Osteoarthritis	50 mg 2 to 3 times daily
		Rheumatoid Arthritis	50 mg 3 to 4 times daily
	Voltaren (diclofenac sodium enteric-coated tablets)	Ankylosing Spondylitis	25 mg 4 times daily, with an extra 25 mg at bedtime if needed
		Osteoarthritis, Rheumatoid Arthritis	50 mg 2 to 3 times daily, or 75 mg twice daily
	Voltaren XR (diclofenac sodium extended-release tablets)	Osteoarthritis	100 mg every day
Rheumatoid Arthritis		75 to 100 mg once or twice daily	

Dosage

Class

▶ ACE INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS (SELECTED)

▶ ANTIDIABETIC AGENTS (SELECTED)

▶ BETA BLOCKERS

Generic Drug Name And Brand Name	Usual Dosage Range*	Maximum Daily Dose	Drug Class	Hypoglycemia Risk**	Weight Change**	GI Symptoms**
Acarbose (Precose(R))	25 to 100 mg ORALLY 3 times daily with meals	60 kg or less: 150 mg; Greater than 60 kg: 300 mg	AGI	not significant	not significant	diarrhea, flatulence
Alogliptin (Nesina(R))	25 mg ORALLY once daily	---	DPP-4 inhibitor	not significant	not significant	not significant
Alogliptin Benzoate/Metformin (Kazano)	alogliptin 12.5 mg/metformin 500 mg to alogliptin 12.5 mg/metformin 1000 mg ORALLY twice daily with meals	alogliptin 25 mg/metformin 2000 mg	DPP-4 inhibitor /Biguanide	***	***	***
Alogliptin/Pioglitazone(Oseni)	alogliptin 25 mg/pioglitazone 15 mg to alogliptin 25 mg/pioglitazone 45 mg ORALLY once daily	alogliptin 25 mg/pioglitazone 45 mg	DPP-4 inhibitor/ TZD	***	***	***

Drug Consults

跳轉到 : **A** B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9

顯示 55 of 628 藥物諮詢文章

Abbreviations


Abuse-Deterrent Opioid Medications

ABVD - Used for Hodgkin's Disease

治療霍奇金氏淋巴瘤的藥物

AC - Used for Breast Cancer

ABVD - Used for Hodgkin's Disease

藥物諮詢 

AC FOLLOWED BY T WITH TRASTUZUMAB

RESPONSE

- DOXOrubicin 25 mg/m(2) IV, days 1 and 15
- Bleomycin 10 mg/m(2) IV, days 1 and 15
- VinBLASTine 6 mg/m(2) IV, days 1 and 15
- Dacarbazine 375 mg/m(2) IV, days 1 and 15 [1]
- Repeat cycle every 28 days

Reference

1. Bonadonna G & Santoro A: ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat Rev 1982; 9(1):21-35.
PubMed Abstract: <http://www.ncbi.nlm.nih.gov/...>
PubMed Article: <http://www.ncbi.nlm.nih.gov/...>

Last Modified: February 06, 2017

REMS (Risk Evaluation & Mitigation Strategy)

跳轉到： [A](#) [B](#) [C](#) [D](#) [E](#) **[F](#)** [G](#) [H](#) [I](#) [J](#) [K](#) [L](#) [M](#) [N](#) [O](#) [P](#) [Q](#) [R](#) [S](#) [T](#) [U](#) [V](#) [W](#) [X](#) [Y](#) [Z](#) [0-9](#)

Displaying 3 of 78 results for "REMS"

Fentanyl 類鴉片止痛劑 Elements to Assure Safe Use, Implementation System, Medication Guide

Fentanyl Citrate

Fingolimod Hydrochloride

Fentanyl

Drug Classes: [Analgesic](#) | [Central Nervous System Agent](#) | [All](#)

Routes: **Sublingual** | **Transdermal**

[簡要解答](#) | [深入解答](#) | [全部結果](#)

[連結到藥品安全訊息和用藥指南](#)

<p>Dosing/Administration</p> <ul style="list-style-type: none"> Adult Dosing Pediatric Dosing FDA Uses Non-FDA Uses Dose Adjustments Administration Comparative Efficacy Place In Therapy 	<p>Medication Safety</p> <p>REMS</p> <p>列印</p> <p>Summary</p> <ul style="list-style-type: none"> to reduce serious adverse outcomes (eg, addiction, unintentional overdose, death) resulting from inappropriate prescribing, misuse, and abuse of extended-release or long-acting opioid analgesics while maintaining patient access to pain medications to mitigate the risk of misuse, abuse, addiction, overdose and serious complications due to medication errors by: prescribing and dispensing transmucosal immediate release fentanyl medicines only to appropriate patients, which includes use only in opioid-tolerant patients; preventing inappropriate conversion between transmucosal immediate release fentanyl medicines; preventing accidental exposure to children and others for whom it was not prescribed
--	--



- Home
- Drug Interactions
- IV Compatibility
- Drug ID
- Drug Comparison
- CareNotes
- NeoFax / Pediatrics
- Other Tools ▾

Fentanyl

Drug Classes: [Analgesic](#) | [Central Nervous System Agent](#) | [All](#)
 Routes: [Sublingual](#) | [Transdermal](#)

1.減少不良的後果(成癮、無心過量、死亡)
2.減輕誤用、濫用、過量、成癮的風險

Substance
 Fentanyl ▾

- Quick Answers
- In-Depth Answers
- All Results

Dosing/Administration

- Adult Dosing
- Pediatric Dosing
- FDA Uses
- Non-FDA Uses
- Dose Adjustments
- Administration
- Comparative Efficacy
- Place In Therapy

Medication Safety

- Contraindications
- Precautions
- Adverse Effects
- Black Box Warning
- REMS**
- Drug Interactions (single)
- IV Compatibility (single)
- Pregnancy & Lactation
- Monitoring
- Do Not Confuse

Medication Safety

REMS



Summary

- To reduce serious adverse outcomes (eg, addiction, unintentional overdose, death) resulting from inappropriate prescribing, misuse, and abuse of extended-release or long-acting opioid analgesics while maintaining patient access to pain medications
- To mitigate the risk of misuse, abuse, addiction, overdose and serious complications due to medication errors by: prescribing and dispensing transmucosal immediate release fentanyl medicines only to appropriate patients, which includes use only in opioid-tolerant patients; preventing inappropriate conversion between transmucosal immediate release fentanyl medicines; preventing accidental exposure to children and others for whom it was not prescribed
- To educate prescribers, pharmacists, and patients on the potential for misuse, abuse, addiction, and overdose of transmucosal immediate release fentanyl medicines
- To inform patients or caregivers about the serious risks associated with transmucosal immediate release and extended-release or long-acting fentanyl treatment

REMS Components

- Medication Guide
- Elements to Assure Safe Use
- Implementation System

Drug Safety Information

- Duragesic(R)
https://www.accessdata.fda.gov/drugsatfda_docs/rems/ERLA_2017-05-26_REMS_Document.pdf
- lonsys(R)
https://www.accessdata.fda.gov/drugsatfda_docs/rems/lonsys_2017-03-29_REMS_Document.pdf

Related Results

- Disease
- Toxicology
- Consumer Drug Information
- Drug Consults
- Index Nominum
- IT- Dialogo Sui Farmaci
- Martindale
- PDR®
- Product Lookup - Martindale
- Product Lookup - RED Book
- Product Lookup - Tox & Drug

查找藥物資訊

可輸入成份或是商品名稱

常見藥品諮詢問題種類

- 劑量(肝腎功能不良、老人、兒童)之調整及投藥方式
- 藥物不良反應
- 藥品交互作用
- 藥物動力學
- 適應症
- 中毒或藥品過量的處理
- 其他，
如：相容性、禁忌、費用、配製、安定性、貯存等

藥師綜合個案的問題

- 醫生考慮

一位75歲有心房顫動合併高血壓的病人，應該使用抗凝血藥物預防中風嗎？

- 病人需求

本人表示之前曾使用過Aspirin，但覺得吃了胃不舒服，所以不太喜歡...

- 家屬關心

擔心使用抗凝血藥物預防中風，是否會增加出血風險？

資料來源：新光吳火獅紀念醫院 劉人瑋藥師

利用Micromedex尋求支持的證據

IBM Micromedex®

我的訂閱 | 開道 | Training Center | 說明 | 下載中心 | 登出

主頁

藥物
相互作用

IV 相容性

藥物
鑒定

藥物
比較

CareNotes

NeoFax / Pediatrics

其他工具 ▾

搜尋藥物、疾病、毒理學及其他資訊

全部

藥物

疾病

毒理學

aspirin



Aspirin

Dosing Aspirin

Adverse Effects Aspirin

Indications Aspirin

Interactions Aspirin

Aspirin (Buffered)

Dosing Aspirin (Buffered)

Adverse Effects Aspirin (Buffered)

Ask Watson

Search Micromedex drug information

Type a quick question...



Learn more

支援和訓練

Micromedex

Consulting & Services

Content Options for MU & More

- Product User Tips & Quick Answers
- Training Center
- User Guide

Read Top News

Support Request

資源

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS



Download Mobile Apps

- 主頁
- 藥物相互作用
- IV 相容性
- 藥物鑒定
- 藥物比較
- CareNotes®
- NeoFax® / Pediatrics
- 其他工具 ▼

關於以下項的搜尋 "WARFRIN" 與任何文件均不相符。

您要尋找的是不是：[afrin](#), [war-far-](#)**warfarin**, [en](#), [warthin](#)

Aspirin- Uses

Aspirin

Drug Classes: [Analgesic](#) | [Antipyretic](#) | [All](#)

Routes: [Oral](#) | [Rectal](#)

Regulatory Authority



FDA



簡要解答

深入解答

全部結果

Dosing/Administration

Adult Dosing

Pediatric Dosing

FDA Uses

Non-FDA Uses

Dose Adjustments

Administration

Comparative Efficacy

Place In Therapy

Medication Safety

Contraindications

Precautions

Adverse Effects

Black Box Warning

REMS

Drug Interactions
(single)

IV Compatibility (single)

Dosing/Administration

Non-FDA Uses

請參閱 '深入解答' 瞭解詳細結果。

列印

- Adenocarcinoma of esophagus; Prophylaxis
- **Atrial fibrillation - Thromboembolic disorder; Prophylaxis**
- Cancer - Thromboembolic disorder; Prophylaxis
- Carotid artery stenosis
- Colorectal cancer, Nonmetastatic, post diagnosis
- Colorectal cancer; Prophylaxis
- Coronary stent stenosis, Subacute; Prophylaxis
- Death, Primary prevention in women
- Disorder of cardiovascular system, Secondary Prophylaxis
- Flushing, Niacin Induced
- In vitro fertilization - Pregnancy-induced hypertension; Prophylaxis

相關結果

替代藥物

毒理學

疾病

Drug Consults

Index Nominum

Martindale

P&T QUIK 報告

PDR®

Product Lookup - Martindale

Product Lookup - RED Book

Product Lookup - Tox & Drug

消費者藥物資訊



Ask Watson

Aspirin- Comparative Efficacy

考量問題：是否有其他藥物可選擇？

ASPIRIN

Drug Classes: [Analgesic](#) | [Antipyretic](#) | [All](#)

Routes: [Oral](#) | [Rectal](#)

Regulatory Authority



FDA

[簡要解答](#)
[深入解答](#)
[全部結果](#)

Atrial fibrillation - Thromboembolism -- Comparative Efficacy

1 / 4 results 用於 atrial fibrillation - thromboembolic disorder; ...

Adult Dosing

Normal Dosage

Important Note

Beers Criteria: Use ca

Oral route

Atrial fibrillation - Throm

a) Guidelines from The

b) Patient With Atrial F

1) Guidelines from

Patients with at

placement, follo

ASPIRIN

Drug Classes: [Analgesic](#) | [Antipyretic](#) | [All](#)

Routes: [Oral](#) | [Rectal](#)

[簡要解答](#)
[深入解答](#)
[全部結果](#)

Atrial fibrillation - Thromboembolism -- Comparative Efficacy

4 / 4 results 用於 atrial fibrillation - thromboembolic disorder; ...

Prior stroke and abnormal LV ejection fraction were significant prognostic risk factors for the development of stroke [1179].

Atrial fibrillation - Thromboembolic disorder; Prophylaxis

a) The second Stroke Prevention in Atrial Fibrillation (SPAF-II) study demonstrated an increase in stroke rate in older compared to younger patients regardless of warfarin or aspirin therapy for non-rheumatic atrial fibrillation. Patients received dose-adjusted warfarin (INR 2.0 to 4.5) or aspirin 325 mg daily. Primary events were defined as ischemic stroke and systemic embolism. In patients 75 years or less (n=715) the rate of primary events in the aspirin group were 1.9% per year compared to 1.3% in the warfarin group (p=0.24). In patients older than 75 years (n=385) the rate of primary events in the aspirin group were 4.8% per year compared to 3.6% per year in the warfarin group (p=0.39). Patients (older than 75) in both the warfarin and aspirin group had similar stroke rates per year with residual deficit (hemorrhagic and ischemic), 4.6% and 4.3% respectively. With regard to all patients (ages combined), annual primary events were lower in the warfarin versus aspirin-treated group (1.9% and 2.7%, respectively; p=0.15). Selecting safe antithrombotic therapy for atrial fibrillation in older patients remains a challenge [1180].

b) Warfarin was superior to aspirin in preventing thromboembolic complications and vascular deaths in chronic, non-rheumatic atrial fibrillation in a controlled study involving 1007 outpatients. In this study, warfarin was given in an open fashion, with the aspirin and placebo arms being double-blind. Warfarin was given in doses to achieve a therapeutic range of 4.2 to 2.8 INR (international normalized ratio); aspirin was given as 75 mg once daily. Anticoagulation with warfarin should be considered in patients with chronic atrial fibrillation as long as contraindications are not present. In a follow-up report of the subjects in this study who received placebo, thromboembolic complications occurred significantly more frequently in those that had a previous myocardial infarction [1181][1182].

c) BAATAF (Boston Area Anticoagulation Trial for Atrial Fibrillation) Study: Warfarin was superior to aspirin for prevention of stroke in patients with nonrheumatic atrial fibrillation. In this study, the annual stroke rate was 0.45% among warfarin users compared to 3.9% among aspirin users and 1.8% among untreated patients. After controlling for various risk factors, the relative stroke rate with warfarin over that of aspirin was 0.029 to 0.64). The relative stroke rate of warfarin over that of untreated patients was also low, however, the 95% CI was extremely wide and included unity, probably as a result of insufficient power of the study [1183].

Atrial fibrillation - Thrombosis; Prophylaxis

b) Warfarin was superior to aspirin in preventing thromboembolic complications and vascular deaths in chronic, non-rheumatic atrial fibrillation in a controlled study involving 1007 outpatients. In this study, warfarin was given in an open fashion, with the aspirin and placebo arms being double-blind.

Warfarin- FDA Uses

1. 考量問題：此藥物的適應症為何？

Home	Drug Interactions	IV Compatibility	Drug ID	Drug Comparison	CareNotes	NeoFax / Pediatrics	Other Tools ▼
------	-------------------	------------------	---------	-----------------	-----------	---------------------	---------------

WARFARIN [Your search: Warfarin]

Drug Classes: [Anticoagulant](#) | [Blood Modifier Agent](#) | [All](#)

Routes: [Intravenous](#) | [Oral](#)

Regulatory Authority



FDA ▼

- Quick Answers
- In-Depth Answers**
- All Results

Dosing/Administration

- Adult Dosing
- Pediatric Dosing
- FDA Uses**
- Non-FDA Uses
- Dose Adjustments
- Administration
- Comparative Efficacy
- Place In Therapy

Medication Safety

- Contraindications
- Precautions
- Adverse Effects
- Black Box Warning
- REMS

Dosing/Administration

FDA Uses

See 'Quick Answers' for summary results.

Warfarin Sodium

- [Atrial fibrillation - Thromboembolic disorder](#)
- [Atrial fibrillation - Thromboembolic disorder: Prophylaxis](#)
- [Myocardial reinfarction; Prophylaxis](#)
- [Prosthetic cardiac valve component embolism](#)
- [Prosthetic cardiac valve component embolism; Prophylaxis](#)
- [Pulmonary embolism](#)
- [Pulmonary embolism; Prophylaxis](#)
- [Thrombosis, Post myocardial infarction; Prophylaxis](#)
- [Venous thromboembolism](#)
- [Venous thromboembolism; Prophylaxis](#)

Atrial fibrillation - Thromboembolic disorder

FDA Labeled Indication

a) Overview

FDA Approval: Adult, yes; Pediatric, no

Efficacy: Adult, Effective

Recommendation: Adult, Class I

View Full Document

Print

Related Results

- [Disease](#)
- [Toxicology](#)
- [Consumer Drug Information](#)
- [Drug Consults](#)
- [Index Nominum](#)
- [IT- Dialogo Sui Farmaci](#)
- [Martindale](#)
- [PDR®](#)
- [Product Lookup - Martindale](#)
- [Product Lookup - RED Book](#)
- [Product Lookup - Tox & Drug](#)

FDA Uses

IBM Micromedex®

My Subscription | Gateway | Training Center | Help | Download Center | Logout

Warfarin

Home	Drug Interactions	IV Compatibility	Drug ID	Drug Comparison	CareNotes	NeoFax / Pediatrics	Other Tools ▼
------	-------------------	------------------	---------	-----------------	-----------	---------------------	---------------

See Drug Consult reference: [Atrial Fibrillation - Drug Treatment Guidelines](#)

Atrial fibrillation - Thromboembolic disorder; Prophylaxis

FDA Labeled Indication

a) Overview

FDA Approval: Adult, yes; Pediatric, no

Efficacy: Adult, Effective

Recommendation: Adult, Class I

Strength of Evidence: Adult, Category A

See Drug Consult reference: [RECOMMENDATION AND EVIDENCE RATINGS](#)

b) Summary:

Product Availability

The marketing and distribution of warfarin sodium for injection has been discontinued as of 5/2/2014 [8]

Indication

Warfarin is indicated for the prophylaxis and treatment of thromboembolic complications as a result of atrial fibrillation (AF) [9]

Evidence (Nonvalvular Atrial Fibrillation)

Direct thrombin inhibitors (DTIs) were similar to adjusted-dose warfarin (INR target, 2 to 3) for reduction in the composite of vascular deaths and ischemic events or composite of stroke, systemic embolic event, MI, and cardiovascular mortality in patients with nonvalvular AF who had 1 or more risk factors for stroke in a meta analysis, and a randomized study of patients underlying electrical cardioversion [10][11]. No significant bleeding differences were observed between warfarin and edoxaban [11]; however, the addition of aspirin to oral anticoagulants significantly increased risk of major bleeding events and hospitalizations related to bleeding [12].

Evidence (Special Populations)

Adjusted-dose warfarin significantly reduced the incidence of the composite endpoint of fatal and nonfatal disabling stroke (ischemic or hemorrhagic), intracranial hemorrhage, and arterial embolism among patients 75 years or older with chronic AF or atrial flutter compared with aspirin [13]; however, use of warfarin did not significantly lower the risk of stroke compared with no warfarin use in a metaanalysis of dialysis patients with AF [14]. The recurrence of hemorrhagic events showed variable results; there were no significant differences on extracranial hemorrhage in elderly patients [13], while warfarin use increased the bleed risk in dialysis patients [14].

是否為核准的適應症用藥？
有建議強度與證據等級嗎？



檢視證據等級與建議強度

RECOMMENDATION, EVIDENCE AND EFFICACY RATINGS

列印

藥物諮詢

頁首

RESPONSE

The Micromedex Efficacy, Strength of Evidence and Strength of Recommendation definitions are outlined below:

Table 1. Strength Of Recommendation

Class I	Recommended	The given test or treatment has been proven to be useful, and should be performed or administered.
Class IIa	Recommended, In Most Cases	The given test, or treatment is generally considered to be useful, and is indicated in most cases.
Class IIb	Recommended, In Some Cases	The given test, or treatment may be useful, and is indicated in some, but not most, cases.
Class III	Not Recommended	The given test, or treatment is not useful, and should be avoided.
Class Indeterminate	Evidence Inconclusive	

Table 2. Strength Of Evidence

Category A	Category A evidence is based on data derived from: Meta-analyses of randomized controlled trials with homogeneity with regard to the directions and degrees of results between individual studies. Multiple, well-done randomized clinical trials involving large numbers of patients.
Category B	Category B evidence is based on data derived from: Meta-analyses of randomized controlled trials with conflicting conclusions with regard to the directions and degrees of results between individual studies. Randomized controlled trials that involved small numbers of patients or had significant methodological flaws (e.g., bias, drop-out rate, flawed analysis, etc.). Nonrandomized studies (e.g., cohort studies, case-control studies, observational studies).
Category C	Category C evidence is based on data derived from: Expert opinion or consensus, case reports or case series.
No Evidence	

Therapeutic Uses

2. 考量問題：使用抗凝血藥物是否可顯著降低中風危險？

Atrial fibrillation - Thromboembolic disorder: Prophylaxis

FDA Labeled Indication

a) Overview

FDA Approval: Adult, yes; Pediatric, no

Efficacy: Adult, Effective

Recommendation: Adult, Class I

Strength of Evidence: Adult, Category A

See Drug Consult reference: [RECOMMENDATION AND EVIDENCE RATINGS](#)

Evidence (Elderly)

Adjusted-dose warfarin significantly reduced the incidence of the composite endpoint of fatal and nonfatal disabling stroke (ischemic or hemorrhagic), intracranial hemorrhage, and arterial embolism among patients 75 years or older with chronic AF or atrial flutter compared with aspirin [15]. The recurrence of hemorrhagic events showed variable results; there were no significant differences on extracranial hemorrhage in elderly patients [15].

4) Elderly

a) Adjusted-dose warfarin reduced the incidence of the composite endpoint of fatal and nonfatal disabling stroke (ischemic or hemorrhagic), intracranial hemorrhage, and other clinically significant arterial embolism compared with aspirin 75 mg/day, among patients 75 years or older with chronic atrial fibrillation or atrial flutter, with no significant difference on major extracranial hemorrhage (BAFTA; N=973) [15].

Summary :
療效與出血風險

詳細說明的建議有...

檢視
資訊來源

Evidence (Elderly)

Adjusted-dose warfarin significantly reduced the incidence of the composite endpoint of fatal and nonfatal disabling stroke (ischemic or hemorrhagic), intracranial hemorrhage, and arterial embolism among patients 75 years or older with chronic AF or atrial flutter compared with aspirin [15]. The recurrence of hemorrhagic events showed variable results; there were no significant differences on extracranial hemorrhage in elderly patients [15].

References

[15] Mant J, Hobbs R, Fletcher K, et al: Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370:493-503.

PubMed Abstract: <http://www.ncbi.nlm.nih.gov/...>

PubMed Article: <http://www.ncbi.nlm.nih.gov/...>

關閉

Adverse Reactions

3. 考量問題：使用抗凝血藥物可能的副作用？

The screenshot shows a web interface for drug information. The top navigation bar includes links for Home, Drug Interactions, IV Compatibility, Drug Identification, Drug Comparison, CareNotes®, NeoFax® / Pediatrics, and Other Tools. The left sidebar lists various drug information categories, with 'Medication Safety' and 'Adverse Effects' highlighted. The main content area is titled 'Adverse Effects' and includes a 'Print' button. A list of adverse effect categories is shown, with 'Hematologic Effects' selected and highlighted in a callout box. The callout box lists the following conditions: Anemia, Bleeding, Blood coagulation disorder, Eosinophilia, Hemolytic anemia, and Hemorrhage. Below this, the 'Cardiovascular Effects' section is visible, listing 'Warfarin Sodium' and its associated conditions: Cholesterol embolus syndrome, Gangrenous disorder, Hemopericardium, and Vasculitis. The 'Cholesterol embolus syndrome' section includes a summary: '1) Systemic atheroemboli and cholesterol microemboli effecting solid organs and extremities, ranging from local necrosis to fatal cases, have occurred during warfarin therapy. Patients may present with'.

Adverse Reactions

Hemorrhage

出血的危險因子

c) Summary

1) Risk factors for major or fatal bleeding in patients taking warfarin sodium include a higher starting INR, age 65 years or older, variable INRs, history of gastrointestinal bleeding, hypertension, cerebrovascular disease, serious heart disease, anemia, malignancy, trauma, renal insufficiency, concomitant drugs, and long duration of warfarin therapy [116]. Other risk factors for a major bleed occurring during warfarin anticoagulation are comorbid conditions, atrial fibrillation, and the first 90 days of warfarin therapy [123][124][125]. Regular monitoring of INR should be performed on all patients. More frequent monitoring, careful dose adjustment, and a shorter duration of therapy may be warranted in patients at high risk for bleeding [116].

b) Prevention and Management

- 1) Perform regular (ie, generally every 1 to 4 weeks) INR monitoring in all treated patients [116]
- 2) Consider more frequent INR monitoring, careful dose titration to desired INR, and shortest possible therapy duration in high-risk patients [116]
- 3) Monitor INR more frequently with treatment initiation, dose adjustment, or withdrawal of other drugs (including botanicals) [116]
- 4) Determine INR immediately before any dental or surgical procedure [116]
- 5) Adjust the dose to maintain INR on the low end of the therapeutic range to continue anticoagulation in patients undergoing minimally invasive procedures [116]
- 6) Do not routinely base vitamin K antagonist (ie, warfarin) therapy interruption solely on clinical prediction rules for bleeding [3].
- 7) If the timeline for anticoagulant reversal is more than 24 hours, interrupt therapy. Oral or parenteral vitamin K may be administered if necessary [116] based on INR [147]
- 8) If expedited (ie, within 1 to 2 hours) reversal is needed, oral or parenteral vitamin K(1) may be administered if necessary [116].
- 9) If emergent (ie, within less than 1 hour) reversal is needed, consider high-dose concentrates (eg, 4-factor prothrombin complex concentrate, 3-factor prothrombin complex concentrate, recombinant factor VIIA, or fresh frozen plasma) [116][147]
- 10) The following are evidence-based guidelines from the American College of Chest Physicians for managing elevated INR or bleeding in patients on vitamin K antagonist (ie, warfarin) therapy:
 - a) INR between 4.5 and 10 with no evidence of bleeding:
 - 1) Routine use of vitamin K is not recommended [3].
 - b) INR greater than 10 with no evidence of bleeding:
 - 1) Administer oral vitamin K [3].
 - c) Vitamin K antagonist-associated major bleeding:
 - 1) Instead of plasma use, achieve rapid anticoagulation reversal with 4-factor prothrombin complex concentrate. Coadminister with vitamin K 5 to 10 mg via slow IV injection rather than attempting reversal with coagulation factor alone [3].

預防與管理： 針對不良反應之處理建議

Monitoring

5. 考量問題：使用抗凝血藥物須監測的項目/頻率？

Dosing/Administration

Adult Dosing

Pediatric Dosing

FDA Uses

Non-FDA Uses

Dose Adjustments

Administration

Comparative Efficacy

Place In Therapy

Medication Safety

Contraindications

Precautions

Adverse Effects

Black Box Warning

達到穩定狀態後的
建議監測頻率

Pregnancy & Lactation

Monitoring

Medication Safety

Monitoring

請參閱 ['簡要解答'](#) 瞭解綜述結果。

檢視完整文件

列印

監測項目與
監測頻率

A) Warfarin Sodium

1) Therapeutic

a) Laboratory Parameters

1) INR

a) Monitor INR daily following the initial warfarin dose until the INR stabilized to the therapeutic range; then periodically based on clinical need, generally every 1 to 4 weeks. Perform additional INR testing when other warfarin products are interchanged with Coumadin(R) or when other drugs (including botanicals) are initiated, discontinued, have dosages changed, or taken irregularly. patients with a high risk of bleeding may require more frequent INR monitoring (manufacturer) [2].

b) Monitor INR up to every 12 weeks in patients with consistently stable INRs, defined as at least 3 months of consistent results with no need to adjust warfarin dosing. Evaluate the INR within 1 to 2 weeks if the patient experiences a single out of range value, below or above the therapeutic INR by 0.5 or less (American College of Chest Physicians guidelines) [1]

In general, the recommended target INR is 2.5 (range, 2 to 3) in adults and pediatric patients in most indications [112][1], except in the following situations:

Target INR is 3 (range 2.5 to 3.5):

相關結果

毒理學

疾病

Drug Consults

eMC SmPC (UK)

Index Nominum

IT- Dialogo Sui Farmaci

Martindale

PDR®

Product Lookup - Martindale

Product Lookup - RED Book Online

Product Lookup - Tox & Drug

消費者藥物資訊

Patient Handouts

6. 考量問題：如何進行用藥指導？

<p>Precautions</p> <p>Adverse Effects</p> <p>Black Box Warning</p> <p>REMS</p> <p>Drug Interactions (single)</p> <p>IV Compatibility (single)</p> <p>Pregnancy & Lactation</p> <p>Monitoring</p> <p>Do Not Confuse</p> <p>Mechanism of Action</p> <p>Mechanism of Action</p> <p>Pharmacokinetics</p> <p>Pharmacokinetics</p> <p>Patient Education</p> <p>Medication Counseling</p> <p>Patient Handouts</p> <p>Toxicology</p> <p>Clinical Effects</p>	<p>Tablet</p> <p>Take your medicine as directed. Your dose may need to be changed several times to find what works best for you.</p> <p>This medicine should come with a Medication Guide. Ask your pharmacist for a copy if you do not have one.</p> <p>Missed dose: Take a dose as soon as you remember. If it is almost time for your next dose, wait until then and take a regular dose. Do not take extra medicine to make up for a missed dose.</p> <p>Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light.</p> <p><u>Drugs and Foods to Avoid:</u></p> <p>Ask your doctor or pharmacist before using any other medicine, including over-the-counter medicines, vitamins, and herbal products.</p> <p>Many medicines and foods affect how warfarin works and affect your PT/INR results. Tell your doctor before you start or stop any medicine, especially the following:</p> <div style="border: 1px solid red; padding: 5px;"> <p>Another blood thinner, including apixaban, cilostazol, clopidogrel, dabigatran, dipyridamole, heparin, prasugrel, rivaroxaban, ticlopidine</p> <p>NSAID pain or arthritis medicine, including aspirin, celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, ketoprofen, ketorolac, naproxen, oxaprozin, piroxicam, sulindac (Check labels for over-the-counter medicines to find out if they contain an NSAID.)</p> <p>SSRI medicine (often treats depression or anxiety), including citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone</p> <p>Ginkgo, echinacea, or St John's wort</p> </div>
--	--

搭配專業術語查詢

主頁

藥物
相互作用

IV 相容性

藥物
鑒定

藥物
比較

CareNotes

NeoFax® /
Pediatrics

其他工具 ▾

搜尋藥物、疾病、毒理學及其他資訊

全部

藥物

疾病

毒理學

Drugs that treat headache|



Drugs that treat **headache**

Drugs that treat **headaches**

Drugs That Treat Headache

顯示： Effective (7) | Evidence Favors Efficacy (31) | Evidence is Inconclusive (2) | Ineffective (0) | Not Rated (0)

Displaying 40 results for "Drugs That Treat Headache"

將檢索結果，依證據等級分類

▼ [Effective \(7 results\)](#)

藥物名稱	Indication	年齡組別
Aspirin	Headache	Adult, Pediatric
Caffeine	Headache; Adjunct	Adult
Dihydroergotamine Mesylate	Cluster headache	Adult
Galcanezumab-gnlm	Episodic cluster headache	Adult
Ibuprofen	Headache	
Naproxen Sodium	Headache	Adult, Pediatric
Sumatriptan Succinate	Cluster headache	Adult

點擊藥品名稱，可進入藥品資訊

▶ [Evidence Favors Efficacy \(31 results\)](#)

▶ [Evidence is Inconclusive \(2 results\)](#)



工具好幫手

主頁

藥物
相互作用

IV 相容性

藥物
鑒定

藥物
比較

CareNotes

NeoFax® /
Pediatrics

其他工具 ▼

藥物相互作用

主頁 **藥物相互作用** IV 相容性 藥物鑒定 藥物比較 CareNotes NeoFax / Pediatrics 其他工具 ▾

藥物相互作用

在搜尋欄位鍵入藥物名稱 (品牌或學名) 。 選擇藥物並按一下 **添加過敏** (新增) 按鈕。

輸入搜尋詞

保健食品：
歐越莓/
山桑子/
覆盆子

- 相符的藥
- Bilberry**
 - Bilberry (Bilberry Extract)
 - Bilberry (Bilberry/Vitamin A/Vitamin E...
 - Bilberry (Homeopathic Substance)
 - Bilberry (Whortleberry)
 - Bilberry Extra Strength
 - Bilberry Extract
 - Bilberry Extract (Beta Carotene/Bilber...
 - Bilberry Extract (Bilberry Extract/Bio...
 - Bilberry Extract (Bilberry)
 - Bilberry Extract/Bioflavonoid/Querceti...

要檢查的藥物：

添加過敏

- Bilberry
- Ibuprofen
- Warfarin

日常用藥：
止痛藥

治療用藥：
AF, 高血壓

添加過敏

帶有星號 (*) 的字母大寫項目表示過敏。

清除 提交

新增過敏症狀。

在搜尋欄位中鍵入過敏症狀。選擇過敏症狀並按一下 **+** (新增) 按鈕。
按一下「更新」將您的選擇加入至「藥物相互作用」中“要檢查的藥物”表單。

輸入過敏症狀:

asp

相符的過敏症狀: (7)

ASPARAGINASE
ASPARAGINE
ASPARAGUS
ASPARTIC ACID
ASPERGILLUS FUMIGATUS
ASPIRIN INTOLERANCE
ASPIRIN

要檢查的過敏症狀:

ASPIRIN
SEAFOOD

取消 **更新**

選擇藥物並按一下 **+** (新增) 按鈕。

要檢查的藥物:

添加過敏

Bilberry
Ibuprofen
Warfarin
ASPIRIN*
SEAFOOD*

Bilberry Extra Strength
Bilberry Extract
Bilberry Extract (Beta Carotene/Bilber...
Bilberry Extract (Bilberry Extract/Bio...
Bilberry Extract (Bilberry)
Bilberry Extract/Bioflavonoid/Querceti...

帶有星號 (*) 的字母大寫項目表示過敏。

清除

提交

Drug Interaction Results

← 修改相互作用

細化方式： 藥物： All 嚴重性： All 文件： All 類型： All

跳轉到： 藥物-藥物 (2) | 複方 (0) | 過敏症狀 (1) | 食物 (12) | 乙醇 (1) | 實驗室 (1) | 抽煙 (1) | 懷孕 (2) | 哺乳期 (2)

Drug-Drug 相互作用 (2)

藥物：

IBUPROFEN -- WARFARIN SODIUM

BILBERRY -- WARFARIN SODIUM

嚴重性：

 Major

 Moderate

文件：

Fair

Fair

綜述：

Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding.

Concurrent use of BILBERRY and ANTICOAGULANTS may result in increased risk of bleeding.

複方 (未找到)

嚴重性
等級不同

Drug-過敏症狀 相互作用 (1)

藥物：

IBUPROFEN -- ASPIRIN

嚴重性：

 Unknown

Warfarin分別和
Ibuprofen、歐越莓
併用皆會增加出血風險

Drug-食物 相互作用 (12)

Ask Watson

定義

嚴重性：



禁忌

禁止同時使用這些藥物。



嚴重

這種相互作用可能危及生命和/或需要醫療干預以儘量減少或避免嚴重的不良影響。



中等

這種相互作用可能導致加重患者的病情和/或需要在治療中發生改變。



較弱

這種相互作用將限制臨床效果。表現可能包括增加副作用的頻率或嚴重程度，但一般不需要在治療中發生重大改變。



未知

未知。

INTERACTION DETAIL

Warning:

Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding.

Clinical Management:

Coadministration of an anticoagulant and an NSAID may increase the risk of serious bleeding relative to the use of either drug alone (Prod Info CALDOLOR® intravenous injection, 2016; Prod Info CELEBREX® oral capsules, 2016; Prod Info COUMADIN® oral tablets, intravenous injection powder for solution, 2015) and may increase the risk of epidural or spinal hematomas that can result in long-term or permanent paralysis in patients who are receiving neuraxial anesthesia or undergoing spinal puncture (Prod Info PRADAXA® oral capsules, 2015; Prod Info SAVAYSA(TM) oral tablets, 2015). If used concomitantly, monitor for signs of bleeding (Prod Info CALDOLOR® intravenous injection, 2016; Prod Info CELEBREX® oral capsules, 2016).

Onset:

Not Specified

INTERACTION DETAIL

Major

Documentation:

Fair

Probable Mechanism:

additive effect on hemostasis

Summary:

Coadministration of an anticoagulant and an NSAID may increase the risk of serious bleeding relative to the use of either drug alone (Prod Info CALDOLOR® intravenous injection, 2016; Prod Info CELEBREX® oral capsules, 2016; Prod Info COUMADIN® oral tablets, intravenous injection powder for solution, 2015) and may increase the risk of epidural or spinal hematomas that can result in long-term or permanent paralysis in patients who are receiving neuraxial anesthesia or undergoing spinal puncture (Prod Info PRADAXA® oral capsules, 2015; Prod Info SAVAYSA(TM) oral tablets, 2015). If used concomitantly, monitor for signs of bleeding (Prod Info CALDOLOR® intravenous injection, 2016; Prod Info CELEBREX® oral capsules, 2016).

列印  關閉 

細化方式： 藥物： All 嚴重性： 2 (Selected) 文件： All 類型： All

跳轉到： 藥物-藥物 (1) | 食物 (2) | 抽煙 (1) | 哺乳期 (1)

Drug-Drug 相互作用 (1)			
藥物：	嚴重性：	文件：	綜述：
IBUPROFEN – WARFARIN SODIUM	Major	Fair	Concurrent use of All NSAIDS may result i
Drug-食物 相互作用 (2)			
藥物：	嚴重性：	文件：	綜述：
WARFARIN SODIUM	Major	Good	Concurrent use of WARFARIN and POMEGRANATE may result in increased warfarin plasma concentrations and increased risk of bleeding.
WARFARIN SODIUM	Major	Good	Concurrent use of WARFARIN and CRANBERRY JUICE may result in an increased risk of bleeding.
Drug-抽煙 相互作用 (1)			
藥物：	嚴重性：	文件：	綜述：
WARFARIN SODIUM	Major	Fair	Concurrent use of CYP1A2 SUBSTRATES and TOBACCO may result in decreased exposure of CYP1A2 substrates.
Drug-哺乳期 相互作用 (1)			
藥物：	嚴重性：	文件：	綜述：
IBUPROFEN	Major	Unknown	Infant risk cannot be ruled out: Available evidence and/ or expert consensus is inconclusive or is inadequate for determining infant risk when Ibuprofen is used during breast-feeding. Weigh the potential benefits of treatment against potential risks before prescribing Ibuprofen during breast-feeding.

選中/取消選中以細化嚴重性設定。

全部選中 | 全部不選

- Contraindicated
- Major
- Moderate
- Minor
- Unknown

取消 更新

定義

嚴重性： 禁忌 嚴重 中等 較弱 未知

文件： 卓越 良好 一般 未知

Ask Watson

多個藥物的IV相容性

IV 相容性

Add at least one drug and press View Compatibility

Drugs (1668)

適用於
焦慮狀態

Select Drug(s) to view Drug-Drug IV Compatibility ×



輸入至少一種藥品

Lorazepam ×

Palonosetron hydrochloride ×

化療用藥

Solutions (257) *optional

Select Solution(s) to view Drug-Solution IV Compatibility ×



需要時輸入溶液

Clear All

View Compatibility

NOTE: IV Compatibility for Drug - Drug Compatibility is displayed in drug pairs

由 Trissel's™ 2 Clinical Pharmaceutics Database (Parenteral Compatibility). 支援。



多個藥物的IV相容性

IV 相容性結果 ◀ 修改相容性


Key :     

Preparation and Storage
Click to view Product and Storage Information

Drugs

-  Lorazepam
-  Palonosetron hydrochloride

Drug-Solution
Drug-Drug: Y-Site
Drug-Drug: Admixture
Drug-Drug: Syringe
相容性 : All

Y-Site Results Summary (View Compatibility Details)	Status
Lorazepam - Palonosetron hydrochloride	 相容

Filter Results

全部選中 | 全部不選

Drugs

- Lorazepam
- Palonosetron hydrochloride

取消 更新

Tip: To see additional information on TPN/TNA compatibility, select a single drug from the list and choose Update.

單一藥物的IV相容性

IV 相容性結果

← 修改相容性

Key :     



相容性 :

All

Preparation and Storage

Click to view Product and Storage Information

Drugs

-  Lorazepam
-  Palonosetron hydrochloride

Filter Results

全部選中 | 全部不選

Drugs

- Lorazepam
- Palonosetron hydrochloride

取消 更新

Drug-Solution

Y-Site

Admixture

Syringe

TPN/TNA

Y-Site Results Summary (View Compatibility Details)

Status

Acetaminophen

 相容

Acyclovir sodium

 相容

Alatrofloxacin mesylate

 相容

Albumin Human

 相容

Aldesleukin

 不相容

Alemtuzumab

 相容

Alfentanil hydrochloride

 相容

藥物鑒定_用印碼查詢

IBM Micromedex®

[My Subscription](#) | [Gateway](#) | [Training Center](#) | [Help](#) | [Download Center](#) | [Logout](#)

Search Micromedex



[Home](#) | [Drug Interactions](#) | [IV Compatibility](#) | **Drug ID** | [Drug Comparison](#) | [CareNotes](#) | [NeoFax / Pediatrics](#) | [Other Tools](#) ▼

Drug Identification

Search: [by Imprint Code](#) | [No Imprint Code? Click here to search by Description](#) ▶

Side 1: Partial Imprint

Side 2: Partial Imprint

Clear

Search

© Copyright IBM Corporation 2018 | [About](#) | [Contact](#) | [Training Center](#) | [User Guide](#) | [Warranty & Disclaimer](#) | [Micromedex.com](#)

藥物鑒定

IBM Micromedex®

My Subscription | Gateway | Training Center | Help | Download Center | Logout

Home | Drug Interactions | IV Compatibility | **Drug ID** | Drug Comparison | CareNotes | NeoFax / Pediatrics | Other Tools ▾

Drug Identification Results

◀ Modify Identification Search Images ▶

Print

6 Matches for: "mrk, 7" Sort all Results by: Imprint ▾

6 Drug Matches for 'M' 1 - 6 (of 6 matching drugs) ◀ First ◀ Previous | Next ▶ Last ▶

Display: ALL | 0-9 | A | B | C | D | E | F | G | H | I | J | K | L | **M** | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

Imprint ▾	Drug Name	Manufacturer	Availability	AAPCC	Poisindex Managements
MRK 711 Singulair	Singulair	Merck Sharp & Dohme	United States	201078	MONTELUKAST
MRK 717 HYZAAR	Hyzaar 50-12.5	Merck Sharp & Dohme	United States	310109	ANGIOTENSIN II ANTAGONISTS DIURETICS
MRK 747 HYZAAR	Hyzaar 100-25	Merck Sharp & Dohme	United States	310109	ANGIOTENSIN II ANTAGONISTS DIURETICS
Mrk; 717	Hyzaar	Merck Frosst	Canada	310109	ANGIOTENSIN II ANTAGONISTS DIURETICS
Mrk; 74; Vioxx	Vioxx	Merck Frosst	Canada	201065	COX-2 INHIBITORS
Mrk; 74; Vioxx	Vioxx	Merck & Company	United States	201065	COX-2 INHIBITORS

藥物鑒定

DRUG INFORMATION

Tox & Drug: [Hyzaar 100-25 ▶](#)
 Martindale: [Hyzaar 100-25 ▶](#)

DRUG NAME: HYZAAR 100-25
INGREDIENTS: HYDROCHLOROTHIAZIDE -- 25 MG
 LOSARTAN -- 100 MG

RELATED DOCUMENTS: POISINDEX MANagements - ANGIOTENSIN II ANTAGONISTS
 POISINDEX MANagements - DIURETICS
 DRUGDEX EVALUATIONS - LOSARTAN
 DRUGDEX EVALUATIONS - HYDROCHLOROTHIAZIDE

COLOR: LIGHT YELLOW
SHAPE: TEARDROP-SHAPE
IMPRINT: HYZAAR , MRK 747
FORM: ORAL TABLET

AVAILABLE-CONTAINER-SIZE: BOTTLE OF 1000 , BOTTLE OF 90 , STRIP OF 100 , BOTTLE OF 4000 , BOTTLE OF 30

AAPCC CODE: 310109 - ANGIOTENSIN RECEPTOR BLOCKER IN COMBINATION WITH DIURETIC

NDC: 00006-0747-00006-0747-00006-0747-00006-0747-00006-0747

EXCIPIENTS: D&L LAKE ; HYDROXYMETHYLCELLULOSE ; HYPROMELLOSES ; MAGNESIUM STEARATE ; PREGELATINIZED STARCH

REGULATORY STATUS: FDA APPROVED

AVAILABILITY: U.S. MARKET

PRODUCT ID: 5724722

藥物資訊

可用容器大小: BOTTLE OF 1000 , BOTTLE OF 90 , STRIP OF 100 , BOTTLE OF 4000 , BOTTLE OF 30

AAPCC 代碼: 310109 - ANGIOTENSIN RECEPTOR BLOCKER IN COMBINATION WITH DIURETIC

輔料: D&C YELLOW NO. 10 ALUMINUM LAKE ; HYDROXYPROPYL CELLULOSE ; HYPROMELLOSE ; LACTOSE, HYDROUS ; MAGNESIUM STEARATE ; MICROCRYSTALLINE CELLULOSE ; PREGELATINIZED STARCH

監管狀態: RX
可用性: UNITED STATES
產品 ID: 5724722
聯絡資訊: MERCK SHARP & DOHME



No Image Available

列印 關閉

藥物鑒定_用外觀查詢

- Home
- Drug Interactions
- IV Compatibility
- Drug ID**
- Drug Comparison
- CareNotes
- NeoFax / Pediatrics
- Other Tools ▾

Drug Identification

Search: by Description [Click here to search by Imprint Code ▾](#)

- Black
- Blue
- Brown
- Clear
- Gold
- Gray
- Green
- Off-White
- Orange
- Pink
- Purple
- Red
- Tan
- White
- Yellow

Shape:

Pattern:


Show Images with results

5 Matches for: "Egg-shape, All Patterns, Pink" Sort all Results by:

1 Drug Match for 'A' 1 - 1 (of 1 matching drugs) [◀First](#) [◀Previous](#) | [Next](#) [▶Last](#)▶▶

Display: [ALL](#) | [0-9](#) | [A](#) | [B](#) | [C](#) | [D](#) | [E](#) | [F](#) | [G](#) | [H](#) | [I](#) | [J](#) | [K](#) | [L](#) | [M](#) | [N](#) | [O](#) | [P](#) | [Q](#) | [R](#) | [S](#) | [T](#) | [U](#) | [V](#) | [W](#) | [X](#) | [Y](#) | [Z](#)

[Hide Images](#)

Image (US)	Imprint ▾	Drug Name
	AMOXIL 125	Amoxil

藥物比較

IBM Micromedex®

[My Subscription](#) | [Gateway](#) | [Training Center](#) | [Help](#) | [Download Center](#) | [Logout](#)

Search Micromedex



Home Drug Interactions IV Compatibility Drug ID **Drug Comparison** CareNotes NeoFax / Pediatrics Other Tools ▾

Drug Comparison

Type the drug name (brand or generic) in the search field. Select the drug and click the ➤ (Add) button.

Enter search term:

warf

Matching drug names: (2)

Warfarin Na
Warfarin Sodium

Drugs to check:

Dabigatran Etexilate Mesylate
Rivaroxaban
Warfarin Sodium

Clear

Submit

© Copyright IBM Corporation 2018 | [About](#) | [Contact](#) | [Training Center](#) | [User Guide](#) | [Warranty & Disclaimer](#) | [Micromedex.com](#)

藥物比較(適應症)_證據等級

Home | Drug Interactions | IV Compatibility | Drug ID | **Drug Comparison** | CareNotes | NeoFax / Pediatrics | Other Tools ▾

Drug Comparison Results ◀ Modify Comparison

Display in Column 1	Display in Column 2
Warfarin Sodium ▾	Dabigatran Etexilate Mesylate ▾
Update	

Jump To: [↑ Top of Page](#) | [Dosing & Indications](#) | [Black Box Warning](#) | [Contraindications/Warnings](#) | [Drug Interactions \(single\)](#) | [Adverse Effects](#) | [Name Info](#) | [Mechanism of Action/Pharmacokinetics](#) | [Administration/Monitoring](#) | [How Supplied](#) | [Toxicology](#) | [Clinical Teaching](#) | [References](#)

FDA-Labeled Indications

[View Detailed information in DRUGDEX ▶](#)

▶ Atrial fibrillation - Thromboembolic disorder

FDA Approval:

- Adult, yes
- Pediatric, no

Efficacy:

- Adult, Effective

Strength of Recommendation:

- Adult, [Class I](#)

▶ Strength of Evidence:

- Adult, [Category A](#)

Atrial fibrillation - Thromboembolic disorder; Prophylaxis

FDA Approval:

- Adult, yes
- Pediatric, no

FDA-Labeled Indications

[View Detailed information in DRUGDEX ▶](#)

▶ Atrial fibrillation - Thromboembolic disorder; Prophylaxis

FDA Approval:

- Adult, yes
- Pediatric, no

Efficacy:

- Adult, Effective

Strength of Recommendation:

- Adult, [Class IIa](#)

▶ Strength of Evidence:

- Adult, [Category B](#)

Deep venous thrombosis, Following parenteral therapy

FDA Approval:

- Adult, yes
- Pediatric, no

藥物比較(不良反應)_一般/嚴重

Home | Drug Interactions | IV Compatibility | Drug ID | **Drug Comparison** | CareNotes | NeoFax / Pediatrics | Other Tools ▾

Drug Comparison Results ◀ Modify Comparison

Display in Column 1

Warfarin Sodium ▾

Display in Column 2

Dabigatran Etexilate Mesylate ▾

Update

Jump To: [↑ Top of Page](#) | [Dosing & Indications](#) | [Black Box Warning](#) | [Contraindications/Warnings](#) | [Drug Interactions \(single Action/Pharmacokinetics\)](#) | [Administration/Monitoring](#) | [How Supplied](#) | [Toxicology](#) | [Clinical Teaching](#) | [References](#) | **Adverse Effects** | [Name Info](#) | [Mechanism of](#)

Adverse Effects

[View Detailed information in DRUGDEX ▶](#)

Common

- **Dermatologic:** Alopecia

Serious

- **Cardiovascular:** Cholesterol embolus syndrome, Tissue necrosis (Less than 0.1%)
- **Dermatologic:** Calciphylaxis, Tissue necrosis (Less than 0.1%)
- **Hematologic:** Hemorrhage, Hemorrhage
- **Immunologic:** Hypersensitivity reaction
- **Musculoskeletal:** Compartment syndrome
- **Neurologic:** Intracranial hemorrhage

Adverse Effects

[View Detailed information in DRUGDEX ▶](#)

Common

- **Gastrointestinal:** Esophagitis, Gastritis, Gastroesophageal reflux disease (Atrial fibrillation, 5.5%), Gastrointestinal hemorrhage (DVT and pulmonary embolism, 0.7% to 3.1%; nonvalvular atrial fibrillation, 6.1%), Gastrointestinal ulcer, Indigestion (DVT and pulmonary embolism, 4.1% to 7.5%)
- **Hematologic:** Hemorrhage (DVT and pulmonary embolism treatment or prophylaxis, 9.7% to 12.3%; nonvalvular atrial fibrillation, 16.6%)

Serious

- **Cardiovascular:** Myocardial infarction (DVT and pulmonary embolism, 0.1% to 0.66%; nonvalvular atrial fibrillation, 0.7%)
- **Gastrointestinal:** Gastrointestinal hemorrhage, Major (DVT and pulmonary embolism, 0.1% to 0.6%; nonvalvular atrial fibrillation, 1.6%)
- **Hematologic:** Hemorrhage, Major (DVT and pulmonary embolism, 0.3% to 2%; nonvalvular atrial fibrillation, 3.3%), Thrombosis
- **Immunologic:** Anaphylaxis
- **Neurologic:** Epidural hematoma. Intracranial hemorrhage (Nonvalvular atria

藥物比較-切換另一藥物

Home | Drug Interactions | IV Compatibility | Drug ID | **Drug Comparison** | CareNotes | NeoFax / Pediatrics | Other Tools ▾

Drug Comparison Results ◀ Modify Comparison

Display in Column 1: Warfarin Sodium

Display in Column 2: **Rivaroxaban** (selected from dropdown menu)

Jump To: [↑ Top of Page](#) | [Dosing & Indications](#) | [Black Box Warning](#) | [Contraindications/Warnings](#) | [Drug Interactions \(single\)](#) | [Adverse Effects](#) | [Name Info](#) | [Mechanism of Action/Pharmacokinetics](#) | [Administration/Monitoring](#) | [How Supplied](#) | [Toxicology](#) | [Clinical Teaching](#) | [References](#)

Adverse Effects

[View Detailed information in DRUGDEX ▶](#)

Common

- Dermatologic:** Alopecia

Serious

- Cardiovascular:** Cholesterol embolus syndrome, Tissue necrosis (Less than 0.1%)
- Dermatologic:** Calciphylaxis, Tissue necrosis (Less than 0.1%)
- Hematologic:** Hemorrhage, Hemorrhage
- Immunologic:** Hypersensitivity reaction
- Musculoskeletal:** Compartment syndrome

Adverse Effects

[View Detailed information in DRUGDEX ▶](#)

Common

- Gastrointestinal:** Esophagitis, Gastritis, Gastroesophageal reflux disease (Atrial fibrillation, 5.5%), Gastrointestinal hemorrhage (DVT and pulmonary embolism, 0.7% to 3.1%; nonvalvular atrial fibrillation, 6.1%), Gastrointestinal ulcer, Indigestion (DVT and pulmonary embolism, 4.1% to 7.5%)
- Hematologic:** Hemorrhage (DVT and pulmonary embolism treatment or prophylaxis, 9.7% to 12.3%; nonvalvular atrial fibrillation, 16.6%)

Serious

- Cardiovascular:** Myocardial infarction (DVT and pulmonary embolism, 0.1% to 0.66%; nonvalvular atrial fibrillation, 0.7%)
- Gastrointestinal:** Gastrointestinal hemorrhage, Major (DVT and pulmonary embolism, 0.1% to 0.6%; nonvalvular atrial fibrillation, 1.6%)
- Hematologic:** Hemorrhage, Major (DVT and pulmonary embolism, 0.3% to 2%; nonvalvular atrial fibrillation, 3.3%), Thrombosis
- Immunologic:** Anaphylaxis


Ask Watson 有問題，問華生！

IBM Micromedex 為何需要華生?



資料太多眼昏花

IBM Micromedex 為何需要華生?



華生相助精準查


怎麼找華生?


IBM Micromedex®



[我的訂閱](#) | [開道](#) | [Training Center](#) | [說明](#) | [下載中心](#) | [登出](#)

主頁 藥物相互作用 IV 相容性 藥物鑒定 藥物比較 CareNotes NeoFax / Pediatrics 其他工具 ▾

全部 藥物 疾病 毒理學


Keyword search 

Type a quick question... 

 [Learn more](#) 

最新消息

- Toxicology & Product Search Updates
- First Lyrica(R) Generics Approved
- Recarbrio(TM) for cUTI and cIAI
- Micromedex Updates on July 24

[Read Top News](#) 


支援和訓練

- Citing Micromedex
- Clinical Consulting & Services
- Integrated Content Options for MU & More
- Product User Tips & Quick Answers
- Training Center
- User Guide


[Support Request](#) 

資源


- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS

 [Download Mobile Apps](#)

怎麼問華生？



點按華生即顯示
問題範例




怎麼問華生？

Ask Watson

Search Micromedex drug information

Type a quick question...



Learn more 

點按Learn more即顯示
智能檢索說明

About IBM Micromedex with Watson

Conversational Search:

Micromedex with Watson uses cognitive computing in the IBM cloud to gather search intent through conversation, provide specific clinical answers, and guide clinicians to relevant evidence.

How Micromedex with Watson Works:

Ask questions in a natural way, the way clinicians ask clinicians. The more specific the question, the more specific the answer. Examples:

- What's the adult dose of lisinopril for hypertension?
- What are approved uses for priligy?
- What are the adverse effects of digoxin?
- Can cefazolin be given IV push?
- How fast can Daptomycin be given?

Micromedex with Watson Understands:

Watson is in medical residency and can answer many drug information questions. The system learns from interaction with users and will be able to answer more sophisticated questions over time. For now, answers are limited to:

- Drug Information (e.g. Drug Classes, Dosing, Administration, Medication Safety, Mechanism of Action, Pharmacokinetics, About)
- Drug Interactions
- IV Compatibility

關閉 

怎麼問華生？

像同事之間一樣問問題

華生現在知道：

藥物資訊 藥物分類、劑量、給藥、
藥物安全性、作用、藥物
動力學、關於機制

藥物交互作用 單一藥物

IV相容性 Solution, Y site,
Admixture, Syringe,
TPN / TNA

華生還不知道：

NeoFax / Pediatrics , Toxicology ,
Disease , Lab , Alternative
Medicine , Reproductive Risk
第三方內容 (例如Martindale, Index
Nominum)

About IBM Micromedex with Watson

Conversational Search:

Micromedex with Watson uses cognitive computing in the IBM cloud to gather search intent through conversation, provide specific clinical answers, and guide clinicians to relevant evidence.

How Micromedex with Watson Works:

Ask questions in a natural way, the way clinicians ask clinicians. The more specific the question, the more specific the answer. Examples:

- What's the adult dose of lisinopril for hypertension?
- What are approved uses for pristin?*
- What are the adverse effects of digoxin?
- Can cefazolin be given IV push?
- How fast can Daptomycin be given?

Micromedex with Watson Understands:

Watson is in medical residency and can answer many drug information questions. The system learns from interaction with users and will be able to answer more sophisticated questions over time. For now, answers are limited to:

- Drug Information (e.g. Drug Classes, Dosing, Administration, Medication Safety, Mechanism of Action, Pharmacokinetics, About)
- Drug Interactions
- IV Compatibility

關閉 X

Demo Slides

對話式檢索範例

就像跟你的同事問問題一樣，
對話將提供簡要解答內容、簡要解答連結、深入解答連結

- Dosing and adjustments 劑量與調整
- Adverse effects 不良反應
- Contraindications 禁忌症
- Precautions 注意事項
- Administration 管理
- More 更多

提問範例：

“What’s the adult dose of warfarin for Atrial fibrillation?”

The screenshot shows the IBM Micromedex Watson Assistant interface. At the top, the title bar reads "IBM Micromedex Watson Assistant". Below the title bar, there is a search bar with three input fields: "Warfarin...", "Atrial fibr...", and "adult", each with a close button (X). To the right of the search bar is a "Clear" button. Below the search bar, there are two suggested questions: "Can I give with food?" and "What patient monitoring is needed?". The main query is displayed in a dark speech bubble: "What's the adult dose of warfarin for Atrial fibrillation". The response is structured as follows: "Here is the adult dosing for warfarin sodium:" followed by two sections: "Atrial fibrillation - Thromboembolic disorder" and "Atrial fibrillation - Thromboembolic disorder; Prophylaxis". Each section contains a list of bullet points detailing dosing instructions. At the bottom of the response, there are two buttons: "Quick Answers Adult Dosing for Warfarin Sodium" and "In-Depth Answers Adult Dosing for Warfarin Sodium". At the very bottom of the interface, there is a feedback prompt: "Was this helpful?" with thumbs up and thumbs down icons, and a text input field labeled "Type something...".

對話式檢索介面

智能過濾器

Warfarin ... x Atrial fibr... x adult x Clear

Here is the adult dosing for warfarin sodium:

Atrial fibrillation - Thromboembolic disorder



- Initial, 2 to 5 mg orally once a day; adjust dose based on the results of INR; usual maintenance, 2 to 10 mg orally once a day
- Following an ischemic stroke or transient ischemic attack, target an INR of 2.5 (range, 2 to 3). Initiation of therapy within 14 days is reasonable, but initiation may be delayed beyond 14 days in presence of high risk for hemorrhagic conversion (guideline dosing)

Atrial fibrillation - Thromboembolic disorder; Prophylaxis

- Initial, 2 to 5 mg orally once a day; adjust dose based on INR; usual maintenance, 2 to 10 mg orally once a day

Quick Answers Adult Dosing for Warfarin Sodium

In-Depth Answers Adult Dosing for Warfarin Sodium

Was this helpful?  

Type something...


簡要解答內容

簡要解答連結

深入解答連結

意見回饋

對話檢索框



IBM Micromedex Watson Assistant

Warfarin... x Atrial fibr... x adult x Clear

Can I give with food?
What patient monitoring is needed?

What's the adult dose of warfarin for Atrial fibrillation

Here is the adult dosing for warfarin sodium:

Atrial fibrillation - Thromboembolic disorder



- Initial, 2 to 5 mg orally once a day; adjust dose based on the results of INR; usual maintenance, 2 to 10 mg orally once a day
- Following an ischemic stroke or transient ischemic attack, target an INR of 2.5 (range, 2 to 3). Initiation of therapy within 14 days is reasonable, but initiation may be delayed beyond 14 days in presence of high risk for hemorrhagic conversion (guideline dosing)

Atrial fibrillation - Thromboembolic disorder; Prophylaxis

- Initial, 2 to 5 mg orally once a day; adjust dose based on INR; usual maintenance, 2 to 10 mg orally once a day

Quick Answers Adult Dosing for Warfarin Sodium

In-Depth Answers Adult Dosing for Warfarin Sodium

Was this helpful?  

Type something...

對話式檢索範例

無論是手滑打錯、語意不明、病名縮寫都沒關係，華生會再次確認，提供你正確答案

提問範例：
adult warfarin AF

Would you like to see the warfarin sodium dosing for atrial fibrillation?

yes


The screenshot shows the Watson Assistant interface. At the top, there are search tabs for 'Warfarin ...', 'Atrial fibr...', and 'adult', along with a 'Clear' button. The chat history shows a user input 'adlut warfarin AF' (with a typo) and a system response asking 'Would you like to see the warfarin sodium dosing for atrial fibrillation?'. The user responds 'yes'. The system then provides dosing information for 'Atrial fibrillation - Thromboembolic disorder' and 'Atrial fibrillation - Thromboembolic disorder; Prophylaxis'. A button at the bottom of the chat area is labeled 'Adult Dosing for Warfarin Sodium'.

對話式檢索範例

您可延續前面問題繼續發問，智慧過濾器將根據前面提出的問題，提供與前述病患相關背景的解答

提問範例：

“Are dose adjustment needed?”



The screenshot shows the Watson Assistant interface. At the top, the title bar reads "Watson Assistant". Below it, there are search filters: "Warfarin ...", "Atrial fibr...", "adult", and a "Clear" button. A dark grey bubble contains the question "Are dose adjustment needed". The main content area displays the following text:

Here are the warfarin sodium dose adjustments:


- Renal impairment: No adjustment necessary
- Geriatric: Consider using lower initial and maintenance dosage
- INR; single out of range value, below or above the therapeutic INR by 0.5 or less, continue current warfarin dose and test INR within 1 to 2 weeks
- discontinuing therapy: abrupt discontinuation is suggested rather than gradual tapering of the dose (ACCP guidelines)
- CYP2C9 and VKORC1 genetic variation: initial dose, based on genotype information
 - - expected doses range, CYP2C9 *1/*1: (VKORC1 GG, AG) 5 to 7 mg; (VKORC1 AA) 3 to 4 mg
 - - expected doses range, CYP2C9 *1/*2: (VKORC1 GG) 5 to 7 mg; (VKORC1 AG, AA) 3 to 4 mg
 - - expected doses range, CYP2C9 *1/*3: (VKORC1 GG, AG) 3 to 4 mg; (VKORC1 AA) 0.5 to 2 mg
 - - expected doses range, CYP2C9 *2/*2: (VKORC1 GG, AG) 3 to 4 mg; (VKORC1 AA) 0.5 to 2 mg
 - - expected doses range, CYP2C9 *2/*3: (VKORC1 GG) 3 to 4 mg; (VKORC1 AG, AA) 0.5 to 2 mg
 - - expected doses range, CYP2C9 *3/*3: (VKORC1 GG, AG, AA) 0.5 to 2 mg
- Pregnancy, mechanical valve: Warfarin to goal INR plus aspirin 75 mg to 100 mg/day during second and third trimesters; during first trimester, warfarin may be continued in patients who are achieving therapeutic INR with doses of 5

At the bottom right of the content area, there is a feedback prompt: "Was this helpful?" with thumbs up and thumbs down icons. Below the content area is a text input field with the placeholder "Type something..."

對話式檢索範例

您可延續前面問題繼續發問，智慧過濾器將根據前面提出的問題，提供與前述病患相關背景的解答

提問範例：
“What patient monitoring is needed?”



The screenshot shows the Watson Assistant interface. At the top, the title bar reads "Watson Assistant". Below it, there are three search filters: "Warfarin...", "Atrial fibr...", and "adult", each with a close button (x). To the right of these filters is a "Clear" button. The main content area displays a question in a speech bubble: "What patient monitoring is needed". Below the question, the assistant's response is shown, starting with "Here is the warfarin sodium monitoring information:". This is followed by a bulleted list of monitoring instructions. At the bottom of the interface, there is a feedback prompt "Was this helpful?" with thumbs up and thumbs down icons, and a text input field with the placeholder "[Type something...]".



Watson Assistant

Warfarin... x Atrial fibr... x adult x Clear

What patient monitoring is needed

Here is the warfarin sodium monitoring information:

- INR: daily following the initial dose until the INR stabilized to the therapeutic range; then periodically based on clinical need, generally every 1 to 4 weeks; additional INR testing when other warfarin products are interchanged with Coumadin(R) or when other drugs (including botanicals) are initiated, discontinued, have dosages changed, or taken irregularly; patients with a high risk of bleeding may require more frequent INR monitoring (manufacturer)
- INR: up to every 12 weeks in patients with consistently stable INRs, defined as at least 3 months of consistent results with no need to adjust warfarin dosing; evaluate INR within 1 to 2 weeks if the patient experiences a single out of range value, below or above the therapeutic INR by 0.5 or less (American College of Chest Physicians guidelines)
- INR: Immediately prior to any dental or surgical procedure
- INR (pediatric); More frequently to ensure target INR is achieved and maintained the low-dose prophylactic target INR is 1.7 (range 1.5 to 1.9)
- INR: More frequently in patients with high risk of bleeding, when starting or stopping other drugs, changing dosages of other drugs, and in patients with renal impairment
- INR (when administered with heparin); Sample at least 5 hours after the last IV bolus dose of heparin, 4 hours after stopping continuous IV heparin infusion, 24 hours after the last subcutaneous heparin injection

Was this helpful?  

[Type something...]

對話式檢索範例

如在前述問題下接續詢問前述藥物與特定藥物的交互作用，結果將提供連結引導您到藥物交互作用的頁面

提問範例：

“Are there interactions with TAMOXIFEN?”

Drug Interactions for Tamoxifen Citrate

Watson Assistant

Tamoxif... x Clear

Drug Interaction Results ← 修改相互作用

細化方式： Drug Tamoxifen Citrate 嚴重性： All 文件： All

跳轉到： Drug-Drug (111) | 過敏症狀 (0) | 食物 (0) | 乙醇 (0) | 實驗室 (0) | 抽煙 (0) | 懷孕 (1) | 哺乳期 (1)

藥物：	嚴重性：	文件：
MESORIDAZINE -- QT INTERVAL PROLONGING DRUGS	Contraindicated	Excellent
WARFARIN [Systemic] -- TAMOXIFEN [Systemic]	Contraindicated	Good
ZIPRASIDONE -- QT INTERVAL PROLONGING DRUGS	Contraindicated	Fair
SAQUINAVIR -- QT INTERVAL PROLONGING DRUGS	Contraindicated	Fair

Are there interactions with TAMOXIFEN

Here are the drug interactions for tamoxifen citrate:
[Drug Interactions for Tamoxifen Citrate](#)

對話式檢索範例

除單一藥物的交互作用清單外，亦可直接查詢多個藥物交互作用

提問範例：
“interactions among
bilberry Losartan
Warfarin ibuprofen?”

The screenshot displays the IBM Micromedex Watson Assistant interface. The main window is titled "Drug Interaction Results" and shows a list of interactions. A callout box on the right highlights the results for ibuprofen, losartan potassium, and warfarin sodium.

藥物:	嚴重性:	文件:	描述:
IBUPROFEN -- WARFARIN SODIUM	Major	Fair	Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding.
IBUPROFEN -- LOSARTAN POTASSIUM	Moderate	Excellent	Concurrent use of ACE INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS and NSAIDS may result in renal dysfunction and/or increased blood pressure.

藥物:	嚴重性:	文件:	描述:
WARFARIN SODIUM	Major	Good	Concurrent use of WARFARIN and POMEGRANATE may result in increased warfarin plasma concentrations and increased risk of bleeding.
WARFARIN SODIUM	Major	Good	Concurrent use of WARFARIN and CRANBERRY JUICE may result in an increased risk of bleeding.

Here are the drug interactions for ibuprofen, losartan potassium and warfarin sodium:


Drug Interactions

對話式檢索範例

若您提出新藥或新病患問題繼續發問，華生將為您重置問題情境並提供相關解答，您無須自行清除前述提問

提問範例：

“what drug treat gout?”



The screenshot shows the Watson Assistant interface. At the top, there are three tabs: "Warfarin...", "Gout", and "adult", each with a close button (x). To the right of the tabs is a "Clear" button. Below the tabs, a dark speech bubble contains the text "what drug treat gout". The main content area displays the following text:

Here are the drugs used for adult gout:

Effective

- Gout
 - [Allopurinol](#)
 - [Colchicine](#)
- Gout - Hyperuricemia
 - [Lesinurad/Allopurinol](#)
- Gout, Refractory to conventional therapy
 - [Pegloticase](#)
- Gout, acute
 - [Naproxen](#)
 - [Naproxen Sodium](#)
- Gout; Prophylaxis
 - [Colchicine](#)
- Gouty arthritis, acute
 - [Indomethacin](#)
 - [Piroxicam](#)
 - [Sulindac](#)
- Gouty arthritis, acute; Adjunct
 - [Betamethasone Sodium Phosphate/Betamethasone A cetate](#)

Evidence favors efficacy

對話式檢索範例

若您提出新藥或新病患問題繼續發問，華生將為您重置問題情境並提供相關解答，或是追問細節以釐清問題，您無須自行清除前述提問

提問範例：

what are the drugs that treat AF

Is it for Adult or Pediatric?

adult

The screenshot shows a chat window titled "Watson Assistant". At the top, there are two input fields: "Atrial fibr..." and "adult", with a "Clear" button to the right. Below the input fields, the assistant's response reads: "You can also ask a series of questions about the same drug: What is the adult dose of digoxin for heart failure? Renal dosing? Contraindications? Adverse effects?". A user input bubble contains the question "what are the drugs that treat AF". The assistant responds with "Is it for Adult or Pediatric?". A second user input bubble contains the word "adult". The assistant then provides a list of drugs under the heading "Effective":

- Atrial fibrillation - Thromboembolic disorder
 - Heparin Sodium
 - Warfarin Sodium
- Atrial fibrillation - Thromboembolic disorder; Prophylaxis
 - Dabigatran Etexilate Mesylate
 - Warfarin Sodium
- Atrial fibrillation and flutter
 - Dofetilide
 - Propafenone Hydrochloride
 - Verapamil Hydrochloride

Q & A Thank You!

客戶服務中心

服務專線：02-7731-5800

服務傳真：02-8226-5022

客戶服務信箱：services@customer-support.com.tw

專人服務時間：週一～週五 9:00~17:30

系統服務時間：全年無休